Tenaya Therapeutics, Inc. (TNYA): Total Liabilities
$23.66M
As of 2025-12-31
$24.13M
As of 2026-06-30
-12.7%
3-year compound annual growth
+22.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $23.66M | -12.7% | 2026-03-11, Balance as of period end |
| 2024-12-31 | $27.09M | -12.9% | 2026-03-11, Balance as of period end |
| 2023-12-31 | $31.09M | -12.6% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $35.57M | -0.3% | 2024-03-18, Balance as of period end |
| 2021-12-31 | $35.66M | +308.9% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $8.72M | n/a | 2022-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Tenaya Therapeutics, Inc. (TNYA) | 2025-12-31 | $23.66M | -12.7% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $138.49M | +193.5% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $30.80M | -21.7% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $19.84M | +13.7% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $62.17M | -22.3% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $4.96M | +46.5% |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $20.97M | -8.6% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $53.03M | +62.1% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
Compare TNYA, INBX, BDTX, IMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗